Harini Bupathi, Esq, joins to discuss the impacts of PBM network terminations and how pharmacies can recover financially.
Feature|Articles|September 4, 2026
The Drug Price Paradox: PBMs, Pharmacies, and the Path to Affordability
Presenting what they believe are the problems and solutions, PCMA CEO David Marin and NCPA CEO Douglas Hoey, RPh, discuss the US drug pricing dilemma.
Advertisement
Advertisement
When Rite Aid announced a slew of retail pharmacy closures across the US, thousands of patients in communities across the country were forced to make arrangements for where they would now be receiving their medications. Tom DePietro, PharmD, a practicing pharmacist and independent pharmacy owner in Pennsylvania, took on new patients from the Rite Aid closures “tactically.”
Related to this article
AJ Barbarito, Esq, provides nuance to the evolving pharmacy reimbursement landscape and how PBMs and pharmacies alike are adapting as they approach 2027.
In part 2 of our pre-election series, detailing key health policies for pharmacists at this year’s midterms, a legal expert touches on MFN pricing, ACA subsidies, and more.
Matt Martin, PharmD, BCSCP, explores current developments in the peptide space and what pharmacists need to know amid FDA decision-making processes.
In celebration of American Pharmacists Month, Melissa McGivney, PharmD, FAPhA, FCCP, provides a snapshot of where the profession has come and where it still has to go.
Independent pharmacies adapt to specialty drugs, biosimilars, cold-chain, and REMS demands.
During American Pharmacists Month, pharmacy teams reflect on their roles and explore ways to enhance patient care.
Melissa McGivney, PharmD, FAPhA, FCCP, helps celebrate American Pharmacists Month and the innovation driving the profession forward amongst US communities.
Advertisement
Advertisement